Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,652 matching trials from the live ClinicalTrials.gov search.
Conditions
Osteoarthritis
Interventions
periosteal electro-acupuncture (osteopuncture).
Device
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Phase 2 Interventional Results available

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

NCT01400958
Conditions
Malignant Glioma
Interventions
Nuvigil®, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Active, not recruiting Phase 2 Interventional Results available

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

NCT03587740
Conditions
Breast Cancer
Interventions
T-DM1
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
14
States / cities
Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Conditions
MDMA Discontinuation Syndrome
Interventions
3,4-methylenedioxymethamphetamine or Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of JULUCA in Hemodialysis

NCT04431518
Conditions
HIV/AIDS, ESRD
Interventions
JULUCA 50Mg-25Mg Tablet
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
Amrou Sarraj
Other
Eligibility
18 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Kansas City, Kansas • St Louis, Missouri + 3 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Influence of Medication on Functional Connectivity

NCT03612713
Conditions
Prescription Drug Abuse (Not Dependent)
Interventions
Oxycodone Medication First, Placebo First
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Opioid-use Disorder, Amphetamine Use Disorders
Interventions
Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Primary Headaches (Migraines, Tension, Cluster Headaches)
Interventions
Osteopathic Manipulative Therapy
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Auburn, Alabama
Conditions
Insulin Resistance, Dementia
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Conditions
Depression, Unipolar, Fall
Interventions
Behavioral Activation, Fall Prevention, Telephone support
Behavioral · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
50 Years to 100 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Austin, Texas
Not listed Phase 1 Interventional Accepts healthy volunteers

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

NCT02584751
Conditions
Gastro Esophageal Reflux Disorder
Interventions
Omeprazole, 24 Hour pH Monitor, Pulmonary Function Examination, Exhaled Nitric Oxide, Exhaled Breath Concentrate (EBC), Bernstein's Acid Clearance Test, Esophageal Motility
Drug · Device · Procedure
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Conditions
Malignant Neoplasms of Independent (Primary) Multiple Sites
Interventions
Tongue Assessment, Stool Sample, Questionnaires, Holter Monitor, Yogurt
Other · Behavioral · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Low Back Pain
Interventions
Hydromorphone ER, Sugar pill
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more
Conditions
Heart Failure
Interventions
LOVAZA (Omega-3), Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Diastolic Heart Failure

NCT02693002
Conditions
Menopause
Interventions
Estradiol/Norethindrone acetate, Placebo
Drug
Lead sponsor
Gretchen Wells
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03776539
Conditions
Impaired Renal Function
Interventions
ELX-02
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Miami, Florida
Conditions
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
Interventions
Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Kenner, Louisiana • Charleston, South Carolina • Richmond, Virginia
Conditions
Telemedicine, Veterans Health, Physical Activity, Mobility
Interventions
Link Team
Behavioral
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan